Iconic Therapeutics fetches $40 mln Series C
Iconic Therapeutics, a biopharmaceutical company focused on serious eye disorders, has raised $40 million in Series C funding. The investors included HBM Healthcare Investments, Cormorant Asset Management, Osage University Partners, MPM Capital, H.I.G. Capital and Lundbeckfund Ventures.
11 January 2016•3 mins read
